Top-selling PBS drug expands

Posted 12 February 2024 AM

The TGA has approved a granule formulation of Vertex's Trikafta for children with cystic fibrosis (CF) as young as two years who have at least one F508del mutation in the CFTR gene.

The top-selling PBS listed drug was previously approved in tablet form for use in people with CF six years and older who have at least one F508del mutation in the CFTR gene.

To see the whole article, please login